Abstract Number: 727 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Background/Purpose: Odanacatib (ODN) is a potent, orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN…Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…Abstract Number: 729 • 2012 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease
Background/Purpose: The G1 and G2 coding variants in the apolipoprotein L1 gene (APOL1; G1: a compound missense allele (glycine-342/methionine-384) and G2: an in-frame deletion (deletion…Abstract Number: 730 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Effect of Strontium Ranelate in Experimental Dog Osteoarthritis: Inhibition of Major Catabolic Pathways
Background/Purpose: To assess the disease modifying (DMOA) effect of strontium ranelate (SrRan) under therapeutic conditions on the progression of structural changes and on the major…Abstract Number: 731 • 2012 ACR/ARHP Annual Meeting
A Systems Biology Approach to Elucidating Pathways Active During the Development of Osteoarthritis
Background/Purpose: OA affects the entire joint but most studies have focused on the disease process in a single tissue. In this study, we identified genes…Abstract Number: 732 • 2012 ACR/ARHP Annual Meeting
Changes in Subchondral Bone Provide a Sensitive Marker for Osteoarthritis and Its Progression: Results From a Large Osteoarthritis Initiative Cohort
Background/Purpose: Change in subchondral bone has been clinically associated with progression of osteoarthritis (OA). Modern image analysis techniques allow accurate, automated identification of bone in…Abstract Number: 691 • 2012 ACR/ARHP Annual Meeting
Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity
Background/Purpose: Multiple cytokines play a role in the immune dysregulation seen in systemic lupus erythematosus (SLE) and the local inflammatory responses that ultimately lead to…Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…Abstract Number: 694 • 2012 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) in the Treatment of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial
Background/Purpose: Tyrosine kinase inhibitors (TKI) which selectively antagonize c-abl and PDGFR have been shown in preclinical models to decrease fibrosis. TKIs are therapies of interest…Abstract Number: 695 • 2012 ACR/ARHP Annual Meeting
Comparison of Intense Pulsed Light and Laser Treatment of Telangiectases in Systemic Sclerosis
Background/Purpose: Cutaneous telangiectases commonly occur in systemic sclerosis (SSc) and are distressing for the patient due to their perceived unsightly appearance. The current standard treatment…Abstract Number: 696 • 2012 ACR/ARHP Annual Meeting
Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database
Background/Purpose: to identify risk factors for early mortality in a large group of recently diagnosed systemic sclerosis (SSc) patients Methods: EUSTAR collects prospectively the Minimal…Abstract Number: 697 • 2012 ACR/ARHP Annual Meeting
Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma
Multivariate Model 1 Adjusted RR 95%CI Multivariate Model 2 Adjusted RR 95%CI Male vs Female 1.4 1.1 – 1.9 Male vs Female 1,4…Abstract Number: 698 • 2012 ACR/ARHP Annual Meeting
External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients
Background/Purpose: The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is…Abstract Number: 699 • 2012 ACR/ARHP Annual Meeting
Endothelial Dysfunction and Vascular Stiffness in Early Diffuse Systemic Sclerosis
Background/Purpose: Vascular dysfunction is a hallmark of systemic sclerosis (SSc). Current theories postulate endothelial injury and dysfunction as an early event in SSc pathogenesis. Prior…
ACR Meeting Abstracts